Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 200 Day Moving Average – What’s Next?

Posted by George Bondi on Aug 19th, 2026

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Get Free Report) (TSE:AUP)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $15.39 and traded as low as $15.07. Aurinia Pharmaceuticals shares last traded at $15.29, with a volume of 996,713 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Zacks Research downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Royal Bank Of Canada raised their price target on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Wall Street Zen downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.67.

Read Our Latest Report on AUPH

Aurinia Pharmaceuticals Stock Performance

The company’s fifty day moving average price is $15.90 and its 200 day moving average price is $15.39. The company has a market cap of $2.13 billion, a PE ratio of 6.99 and a beta of 1.42. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.04. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The business had revenue of $58.57 million for the quarter, compared to analysts’ expectations of $80.45 million. On average, equities research analysts predict that Aurinia Pharmaceuticals Inc will post 0.79 earnings per share for the current year.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Kevin Tang bought 343,620 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were purchased at an average price of $15.28 per share, for a total transaction of $5,250,513.60. Following the purchase, the chief executive officer directly owned 12,838,101 shares of the company’s stock, valued at approximately $196,166,183.28. This represents a 2.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders purchased 814,606 shares of company stock valued at $12,455,129. 10.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BOK Financial Private Wealth Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $32,000. Global Retirement Partners LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter worth about $41,000. Quantbot Technologies LP bought a new position in Aurinia Pharmaceuticals during the second quarter valued at about $45,000. Northwestern Mutual Wealth Management Co. bought a new position in Aurinia Pharmaceuticals during the third quarter valued at about $48,000. Finally, Frazier Financial Advisors LLC increased its holdings in Aurinia Pharmaceuticals by 411.9% during the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock worth $51,000 after buying an additional 2,793 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

(Get Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.